Compass Therapeutics (CMPX) Accumulated Depreciation & Amortization: 2023-2025
Historic Accumulated Depreciation & Amortization for Compass Therapeutics (CMPX) over the last 3 years, with Sep 2025 value amounting to $6.6 million.
- Compass Therapeutics' Accumulated Depreciation & Amortization fell 1.43% to $6.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $26.1 million, marking a year-over-year increase of 0.41%. This contributed to the annual value of $6.4 million for FY2024, which is 1.50% up from last year.
- Compass Therapeutics' Accumulated Depreciation & Amortization amounted to $6.6 million in Q3 2025, which was up 0.29% from $6.6 million recorded in Q2 2025.
- Compass Therapeutics' 5-year Accumulated Depreciation & Amortization high stood at $6.7 million for Q3 2024, and its period low was $5.8 million during Q1 2023.
- Over the past 3 years, Compass Therapeutics' median Accumulated Depreciation & Amortization value was $6.4 million (recorded in 2024), while the average stood at $6.4 million.
- Its Accumulated Depreciation & Amortization has fluctuated over the past 5 years, first climbed by 11.44% in 2024, then declined by 1.43% in 2025.
- Compass Therapeutics' Accumulated Depreciation & Amortization (Quarterly) stood at $6.3 million in 2023, then grew by 1.50% to $6.4 million in 2024, then decreased by 1.43% to $6.6 million in 2025.
- Its Accumulated Depreciation & Amortization stands at $6.6 million for Q3 2025, versus $6.6 million for Q2 2025 and $6.5 million for Q1 2025.